Orrick Advises Bayer on $250 Million Century Therapeutics Financing


Orrick has advised lead investor Leaps by Bayer, the investment arm of global life sciences company Bayer, in its $215 million investment commitment in Century Therapeutics. Incubated by Versant Ventures, in partnership with Fujifilm subsidiary Fujifilm Cellular Dynamics, Century is developing off-the-shelf immune cell therapies for cancer.

Versant and Fujifilm also participated in the financing, bringing the total investment commitment to $250 million. The proceeds will enable Century to advance multiple immune oncology treatment programs into its clinic.

The Orrick team advising Bayer was led by Matthew Gemello and included Ramy Shweiky, Thomas Joraanstad, Max Hyatt, Eric Wall, Alex Okuliar and Diana Gillis.